Is SHC a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Sotera Health (SHC) rests on Contracted volume and repeat pricing: More than 90% of Sterigenics revenue and roughly 90% of Nordion revenue in 2025 came from customers under multi-year contracts, many carrying variable price clauses. The bear case rests on the ethylene oxide tort docket is the dominant, partly quantified risk. Analysts covering it publish targets from $18.00 to $25.00 against a $19.57 price, so even the professionals disagree by 31% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Sotera Health provides the step a medical product has to pass before it can be sold: killing whatever is living on it. Sterigenics, the largest of the three units, runs contract sterilization plants using gamma irradiation, ethylene oxide and electron beam, and has done that work for more than 90 years. Nordion supplies the cobalt-60 that makes gamma sterilization possible, along with the irradiator systems that house it, and the company estimates gamma handles roughly 30% of single-use medical device sterilization worldwide. Nelson Labs sells microbiological and analytical chemistry testing (over 900 distinct tests) plus the regulatory advisory work customers need to validate a sterilization method and defend it to a regulator. Revenue for the twelve months to June 30, 2026 was ~$1.22 billion across 62 facilities and more than 3,000 employees. The customer list is concentrated at the top of the industry: over 40 of the top 50 medical device companies and nine of the ten largest global pharmaceutical companies. More than 90% of both Sterigenics and Nordion revenue in 2025 came from customers on multi-year contracts, so volumes track device production rather than any discretionary spending cycle. Pricing and volume are the two levers the numbers turn on, and both worked in the first half of 2026. Second-quarter revenue rose 9.2% to $321.4 million, with Sterigenics up 8.6%, Nordion up 15.8% on the timing of cobalt-60 harvests, and Nelson Labs up 6.3% after a weak 2025. Adjusted EBITDA margin reached 51.6% in the quarter, a level very few healthcare-services businesses hold, and management raised full-year guidance on August 6, 2026 to $1.236 billion to $1.254 billion of revenue and $634 million to $643 million of adjusted EBITDA. The capital structure explains much of the equity story. Sotera carried ~$2.27 billion of total debt against $357.0 million of cash at June 30, 2026, and net leverage of 3.0x reached the top of the company's long-term target range for the first time. A May 2026 term loan repricing cut the spread by 25 basis points and saves ~$3.5 million a year. At ~$19.57 a share the equity is worth ~$5.58 billion, or roughly 12x trailing adjusted EBITDA on an enterprise value near $7.5 billion. The gap between that multiple and what infrastructure-like healthcare assets usually fetch is where the ethylene oxide tort docket sits.
The bull case: what would have to be true for $25.00
The most optimistic published target on SHC is $25.00, +27.7% from the $19.57 price as of August 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Contracted volume and repeat pricing
More than 90% of Sterigenics revenue and roughly 90% of Nordion revenue in 2025 came from customers under multi-year contracts, many carrying variable price clauses. Sterigenics grew 8.3% in 2025 to $755.8 million on 4.1% pricing and 3.6% volume/mix, then added 9.1% in the first half of 2026 to $397.7 million. Segment income margin was 54.6% for 2025 and improved another 53 basis points in the second quarter of 2026. Sterilization is a required step rather than a purchase decision, so the volume base moves with device production instead of with hospital capital budgets.
2. Nordion's cobalt-60 position and the harvest cycle
Nordion is the leading global supplier of cobalt-60 outside state-linked producers, and its revenue is lumpy because cobalt is harvested from nuclear reactors on a schedule rather than manufactured continuously. Second-quarter 2026 revenue rose 15.8% to $49.1 million and first-half revenue rose 21.6% to $91.2 million, driven mostly by harvest timing. Segment margin was 57.3% in 2025, the highest of the three units. Cobalt-60 decays at roughly 12% a year, so customers replenish sources whether or not their own volumes grow, giving the unit a subscription-like floor. Competing production sits in Argentina, India, Russia and China, and the Russian supplier has faced export constraints in recent years.
3. Leverage coming down, and interest expense with it
Net leverage fell to 3.0x at June 30, 2026, reaching the 2.0x to 3.0x range management has pointed at since the IPO. Interest expense, net was $69.2 million in the first half of 2026 against $81.5 million a year earlier, a $12.4 million reduction that drops straight through. In May 2026 the company repriced ~$1.42 billion of first lien term loans, cutting the spread to SOFR plus 2.25% and saving ~$3.5 million of annual interest. Full-year 2026 interest expense guidance came down to $135 million to $142 million. Available liquidity stood at ~$950 million with nothing drawn on the $600 million revolver.
4. The sponsor register cleared out
Warburg Pincus and GTCR took Sotera public in November 2020 and held control for more than five years through a stockholders agreement carrying board designation rights. Affiliates sold 25,000,000 shares at $15.27 on March 6, 2026 and a final 31,838,253 shares at $15.168 on May 13, 2026, after which no sponsor ownership remains and the stockholders agreement terminated by its terms. Sponsor-designated directors have since left the board: Constantine Mihas of GTCR effective March 16, 2026 and James Neary of Warburg Pincus effective August 13, 2026. Alton Shader took over as chief executive from Michael Petras under an offer dated May 1, 2026. The float is now the whole company, and the queue of scheduled secondary sales that capped the stock is gone.
The bear case: what would have to be true for $18.00
The most pessimistic published target is $18.00, -8.0% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Sotera Health is worth if the risks below bite instead of the drivers above.
The ethylene oxide tort docket is the dominant, partly quantified risk. Sterigenics and affiliates have already agreed to pay $408.0 million to settle over 880 Willowbrook, Illinois claims (term sheets January 2023, finalized June 2023), $35 million for 79 Atlanta claims in October 2023, $30.9 million for 97 more Illinois claims in April 2025 and $34.0 million for 129 further Illinois claims in July 2025. A single Cook County jury returned a $358.7 million verdict in 2022, of which $320 million was punitive. As of July 31, 2026 the open inventory was approximately 500 Georgia personal-injury and wrongful-death claims, ~305 Georgia property-devaluation suits, ~150 California claims tied to the Vernon facilities with initial trials scheduled for January and April 2027, and ~15 Illinois cases. The company states that losses in the remaining cases are not probable and carries no reserve for them, so an adverse verdict would land unprovided for. Georgia rulings currently favor the defense, since the trial court excluded plaintiffs' general causation experts and entered summary judgment in March 2026, but those rulings are on appeal. Regulation is the second exposure. The EPA's March 2024 NESHAP rules require permanent total enclosure capture, higher control efficiencies and continuous emissions monitoring at ethylene oxide sterilizers. A July 2025 Clean Air Act proclamation granted Sotera's facilities a two-year exemption, and a January 2026 suit in the District of Columbia seeks to invalidate that exemption and restore the original deadline. Capital expenditure guidance of $200 million to $225 million for 2026, against ~$1.24 billion of revenue, reflects part of that compliance burden and keeps free cash flow far below adjusted EBITDA. A separate FIFRA interim decision issued in January 2025 phases in tighter worker exposure limits over one to ten years. Three smaller items sit behind those. Total debt of ~$2.27 billion against $665.6 million of book equity leaves limited cushion if volumes stall. The United States has a single industry supplier of ethylene oxide. And Nelson Labs shrank 3.9% in 2025 and grew only 0.9% in constant currency in the first half of 2026, a reminder that the testing unit does not behave like the sterilization ones.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding SHC already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on SHC
9 analysts cover SHC, with an average target of $22.72 (+16.1% against $19.57) and a split of 8 buy, 2 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the SHC forecast and price target page.
How is SHC valued? (as of August 2026)
Snapshot for SHC as of August 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$1.22 billion for the twelve months to June 30, 2026, up ~8% from ~$1.16 billion in fiscal 2025 and ~$1.10 billion in fiscal 2024. Second-quarter 2026 revenue was $321.4 million, up 9.2% year over year and 8.0% in constant currency. On August 6, 2026 management raised full-year guidance to $1.236 billion to $1.254 billion, implying 5.25% to 6.75% constant-currency growth plus an estimated 100 basis points of currency benefit.
- Earnings and EPS: GAAP net income of ~$163.5 million for the twelve months to June 30, 2026, against $77.9 million in fiscal 2025 and $44.3 million in fiscal 2024. Trailing diluted EPS is $0.57, putting the shares near 34x reported earnings. The year-on-year comparison flatters 2026 because fiscal 2025 absorbed $64.9 million of Illinois settlement charges and heavier intangible amortization. Q2 2026 net income was $53.6 million ($0.19 diluted) versus $8.0 million ($0.03) a year earlier; adjusted EPS of $0.26 rose 30%, and full-year adjusted EPS guidance is $0.95 to $1.01.
- Segment mix and margins: For fiscal 2025, Sterigenics contributed $755.8 million of revenue (65% of the total) at a 54.6% segment margin, Nordion $187.6 million (16%) at 57.3%, and Nelson Labs $220.2 million (19%) at 33.3%. In the second quarter of 2026 those revenues were $211.6 million, $49.1 million and $60.7 million, with segment income of $118.1 million, $28.0 million and $19.6 million. Consolidated adjusted EBITDA margin was 51.6% in the quarter and 51.1% on a trailing twelve-month basis. Nelson Labs is the swing factor, having fallen 3.9% in 2025.
- Cash flow and capital spending: Net cash from operating activities was $117.9 million in the first half of 2026 versus $112.9 million a year earlier, with $88 million of it in the second quarter. Capital expenditure was $92.6 million in the half against $51.1 million in the prior-year half, and full-year 2026 guidance is $200 million to $225 million, close to 17% of revenue. Free cash flow is therefore a small fraction of the $621.6 million of trailing adjusted EBITDA, because cobalt supply, plant capacity and emissions controls all consume cash.
- Balance sheet: Total debt of ~$2.27 billion and unrestricted cash of $357.0 million at June 30, 2026, for net debt near $1.91 billion and a net leverage ratio of 3.0x, the top of the 2.0x to 3.0x target. Total assets were $3.31 billion, total liabilities $2.64 billion and total equity $665.6 million, including goodwill of $1.09 billion. Available liquidity was ~$950 million with the $600 million revolver undrawn. The May 2026 repricing set ~$1.42 billion of term loans at SOFR plus 2.25%.
- Market pricing: The shares closed at $19.57 on August 21, 2026, against a 52-week range of $13.09 to $19.85, for a market capitalization of ~$5.58 billion on ~285.4 million shares outstanding (289 million to 291 million weighted-average diluted shares guided for 2026). Enterprise value is roughly $7.5 billion, or ~12x trailing adjusted EBITDA of $621.6 million and ~11.7x the midpoint of 2026 guidance. Trailing P/E is ~34x, the forward multiple on guided adjusted EPS is ~20x, and price to trailing sales is ~4.6x. Sotera pays no dividend.
Roughly 12x enterprise value to adjusted EBITDA is a modest price for a business earning 51% EBITDA margins on largely contracted revenue from a regulated, hard-to-replicate asset base. The discount is the litigation. Sotera carries no reserve for the ~970 ethylene oxide claims still outstanding, so the multiple embeds an unpriced tail rather than a known cost. The trailing GAAP P/E of ~34x, meanwhile, reflects amortization, interest and settlement charges that the adjusted figures strip out.
How do you decide if SHC is a buy?
Rather than asking whether SHC is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold SHC indirectly through an index or sector ETF before adding more.
What would change your mind on SHC
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Contracted volume and repeat pricing stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: the ethylene oxide tort docket is the dominant, partly quantified risk fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the SHC stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about SHC against your real portfolio and see your actual exposure before deciding.
Investing in Sotera Health with AI
Connect the broker you already use and ask Walnut's AI how SHC fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is SHC a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Contracted volume and repeat pricing, with revenue (ttm) at ~$1.22 billion for the twelve months to June 30, 2026, up ~8% from ~$1.16 billion in fiscal 2025 and ~$1.10 billion in fiscal 2024. Second-quarter 2026 revenue was $321.4 million, up 9.2% year over year and 8.0% in constant currency. On August 6, 2026 management raised full-year guidance to $1.236 billion to $1.254 billion, implying 5.25% to 6.75% constant-currency growth plus an estimated 100 basis points of currency benefit.. The bear case rests on the ethylene oxide tort docket is the dominant, partly quantified risk. Analysts covering it are spread from $18.00 to $25.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell SHC?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The ethylene oxide tort docket is the dominant, partly quantified risk. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $18.00, -8.0% from the $19.57 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for SHC?
+
Contracted volume and repeat pricing. More than 90% of Sterigenics revenue and roughly 90% of Nordion revenue in 2025 came from customers under multi-year contracts, many carrying variable price clauses. The most optimistic analyst target on SHC is $25.00, +27.7% from the $19.57 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for SHC?
+
The ethylene oxide tort docket is the dominant, partly quantified risk. Sterigenics and affiliates have already agreed to pay $408.0 million to settle over 880 Willowbrook, Illinois claims (term sheets January 2023, finalized June 2023), $35 million for 79 Atlanta claims in October 2023, $30.9 million for 97 more Illinois claims in April 2025 and $34.0 million for 129 further Illinois claims in July 2025. A single Cook County jury returned a $358.7 million verdict in 2022, of which $320 million was punitive. As of July 31, 2026 the open inventory was approximately 500 Georgia personal-injury and wrongful-death claims, ~305 Georgia property-devaluation suits, ~150 California claims tied to the Vernon facilities with initial trials scheduled for January and April 2027, and ~15 Illinois cases. The company states that losses in the remaining cases are not probable and carries no reserve for them, so an adverse verdict would land unprovided for. Georgia rulings currently favor the defense, since the trial court excluded plaintiffs' general causation experts and entered summary judgment in March 2026, but those rulings are on appeal. Regulation is the second exposure. The EPA's March 2024 NESHAP rules require permanent total enclosure capture, higher control efficiencies and continuous emissions monitoring at ethylene oxide sterilizers. A July 2025 Clean Air Act proclamation granted Sotera's facilities a two-year exemption, and a January 2026 suit in the District of Columbia seeks to invalidate that exemption and restore the original deadline. Capital expenditure guidance of $200 million to $225 million for 2026, against ~$1.24 billion of revenue, reflects part of that compliance burden and keeps free cash flow far below adjusted EBITDA. A separate FIFRA interim decision issued in January 2025 phases in tighter worker exposure limits over one to ten years. Three smaller items sit behind those. Total debt of ~$2.27 billion against $665.6 million of book equity leaves limited cushion if volumes stall. The United States has a single industry supplier of ethylene oxide. And Nelson Labs shrank 3.9% in 2025 and grew only 0.9% in constant currency in the first half of 2026, a reminder that the testing unit does not behave like the sterilization ones. The most pessimistic published target is $18.00, -8.0% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Sotera Health do?
+
Sotera Health sterilizes medical products and runs lab testing, through Sterigenics, Nordion and Nelson Labs.
What would have to change for SHC to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Contracted volume and repeat pricing) stalling in the reported numbers rather than in the narrative, the risk above (the ethylene oxide tort docket is the dominant, partly quantified risk) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Sotera Health do?
+
Sotera Health is a contract sterilization and testing provider for the medical device, pharmaceutical and food industries, operating 62 facilities in more than 50 countries with over 3,000 employees. It works through three brands. Sterigenics runs outsourced sterilization plants using gamma irradiation, ethylene oxide and electron beam. Nordion supplies cobalt-60, the radioactive source that makes gamma sterilization possible, plus the irradiator systems that hold it. Nelson Labs performs more than 900 microbiological and analytical chemistry tests and sells regulatory advisory services. Most medical products cannot be sold until they have been sterilized and validated, so the work is a required step in a customer's supply chain rather than an optional one. Over 40 of the top 50 device makers and nine of the ten largest pharmaceutical companies are customers.
Why does Sotera Health stock trade at a low multiple for its margins?
+
At ~$19.57 in August 2026 Sotera trades near 12x enterprise value to trailing adjusted EBITDA of $621.6 million, low for a business earning a 51% EBITDA margin on largely contracted revenue. Two things account for the gap. The ethylene oxide tort docket is open, with roughly 970 personal-injury and property claims outstanding as of July 31, 2026 and no reserve taken against them, so the potential cost is unquantified rather than absent. Second, the balance sheet still carries ~$2.27 billion of debt against $665.6 million of book equity at 3.0x net leverage, which limits how much EBITDA reaches shareholders after $135 million to $142 million of guided 2026 interest and $200 million to $225 million of capital expenditure.
What is the ethylene oxide litigation against Sotera Health?
+
Sterigenics and related subsidiaries have been sued by individuals alleging cancers and other injuries from low-level environmental exposure to ethylene oxide emitted from sterilization plants. The claims are individual suits, not class actions. A Cook County jury awarded $358.7 million against the company in 2022 over the former Willowbrook, Illinois facility, including $320 million in punitive damages, after which the company agreed in January 2023 to pay $408.0 million to settle over 880 Illinois claims. Further settlements followed: $35 million for 79 Atlanta claims, $30.9 million for 97 Illinois claims in April 2025 and $34.0 million for 129 more in July 2025. As of July 31, 2026 about 500 Georgia personal-injury claims, 305 Georgia property claims, 150 California claims and 15 Illinois cases remain pending.
Walnut is informational, not investment advice, and gives no verdict on SHC. Analyst targets referenced here come from a August 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.